Analysts Anticipate Repligen Co. (NASDAQ:RGEN) Will Announce Earnings of $0.73 Per Share

Brokerages expect Repligen Co. (NASDAQ:RGENGet Rating) to report earnings of $0.73 per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Repligen’s earnings. The highest EPS estimate is $0.80 and the lowest is $0.66. Repligen posted earnings of $0.79 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 7.6%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Repligen will report full-year earnings of $3.12 per share for the current year, with EPS estimates ranging from $3.09 to $3.26. For the next fiscal year, analysts forecast that the company will post earnings of $3.64 per share, with EPS estimates ranging from $3.50 to $4.12. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Repligen.

Repligen (NASDAQ:RGENGet Rating) last announced its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.20. Repligen had a return on equity of 11.13% and a net margin of 19.86%. The business had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $185.48 million. During the same quarter last year, the business posted $0.68 earnings per share. The business’s revenue for the quarter was up 44.5% on a year-over-year basis.

A number of brokerages have recently weighed in on RGEN. Craig Hallum dropped their price target on Repligen from $286.00 to $274.00 in a research report on Thursday, April 28th. StockNews.com began coverage on Repligen in a research report on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating and set a $190.00 price objective for the company. in a research report on Monday, February 21st. Finally, SVB Leerink dropped their price objective on Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, February 18th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $285.57.

In other news, Director Thomas F. Ryan, Jr. sold 2,000 shares of Repligen stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $198.03, for a total value of $396,060.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.10% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. increased its holdings in Repligen by 3.9% during the 1st quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company’s stock worth $330,315,000 after purchasing an additional 65,550 shares during the last quarter. WCM Investment Management LLC increased its holdings in shares of Repligen by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 1,392,617 shares of the biotechnology company’s stock valued at $261,937,000 after acquiring an additional 30,708 shares during the last quarter. State Street Corp increased its holdings in shares of Repligen by 2.5% in the 1st quarter. State Street Corp now owns 1,381,031 shares of the biotechnology company’s stock valued at $259,758,000 after acquiring an additional 33,660 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Repligen by 25.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,063,338 shares of the biotechnology company’s stock valued at $307,294,000 after acquiring an additional 217,697 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Repligen by 12.0% in the 1st quarter. Bank of New York Mellon Corp now owns 849,212 shares of the biotechnology company’s stock valued at $159,729,000 after acquiring an additional 90,765 shares during the last quarter. Institutional investors own 86.82% of the company’s stock.

Shares of RGEN stock traded down $0.10 during mid-day trading on Friday, reaching $154.53. The stock had a trading volume of 247,865 shares, compared to its average volume of 660,636. Repligen has a 12-month low of $137.21 and a 12-month high of $327.32. The company has a market cap of $8.41 billion, a P/E ratio of 61.08 and a beta of 0.98. The business has a 50-day simple moving average of $165.24 and a 200 day simple moving average of $205.26.

About Repligen (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.